Kyntra Bio, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Kyntra Bio, Inc. filed a Form 8-K reporting the results of its 2026 Annual Meeting of Stockholders held on June 12, 2026. Stockholders voted on three key proposals. First, Michael Kauffman, M.D., Ph.D., was elected as a Class III director to serve until the 2029 annual meeting, receiving approximately 96.04% of the votes cast. Second, stockholders approved, on an advisory basis, the compensation of the company’s named executive officers as disclosed in the definitive proxy statement. Third, the appointment of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified with an overwhelming majority. The filing also noted the continuing terms of Class I and Class II directors. No material changes to operations, clinical trials, or financial guidance were disclosed in this filing.